ライフサイエンスコーパス: adrenocortical carcinoma

1 HGF/cMET expression and cancer hallmarks of adrenocortical carcinoma.

2 vestigate efficacy in patients with advanced adrenocortical carcinoma.

3 dualised and improved therapeutic options in adrenocortical carcinoma.

4 survival in patients with radically resected adrenocortical carcinoma.

5 velop gonadal tumors and-when gonadectomized-adrenocortical carcinoma.

6 mg/m2 had improvement in liver metastases of adrenocortical carcinoma.

7 There were no occult adrenocortical carcinomas.

8 's sarcomas, gliomas, rhabdomyosarcomas, and adrenocortical carcinomas.

9 To gain insight into the pathogenesis of adrenocortical carcinoma (ACC) and whether there is prog

10 utant, R337H (p53tet-R337H), associated with adrenocortical carcinoma (ACC) in children, can be conve

11 Adrenocortical carcinoma (ACC) is a rare but aggressive

12 Adrenocortical carcinoma (ACC) is a rare malignancy with

13 Adrenocortical carcinoma (ACC) is a rare pediatric malig

14 Adrenocortical carcinoma (ACC) is an endocrine malignanc

15 pathway activity lead to poorer prognosis in adrenocortical carcinoma (ACC) patients.

16 ng could expose novel targets for therapy in adrenocortical carcinoma (ACC), a rare and lethal cancer

17 tudy, we investigated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy

18 ts who underwent curative intent surgery for adrenocortical carcinoma (ACC).

19 mplicated in sporadic and syndromic forms of adrenocortical carcinoma (ACC).

20 ily member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC).

21 a comprehensive genomic characterization of adrenocortical carcinoma (ACC).

22 s pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyp

23 spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft ti

24 we generated transcriptional profiles of 11 adrenocortical carcinomas (ACCs), 4 adrenocortical adeno

25 relative to general population rates were in adrenocortical carcinoma and phyllodes tumour.

26 rozygosity in Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast

27 eukemia, melanoma, duodenal adenocarninomas, adrenocortical carcinomas, and neuroblastomas.

28 uence level, is required to fully understand adrenocortical carcinoma biology and apply that knowledg

29 ecent advances that promise to shed light on adrenocortical carcinoma biology.

30 and muscle, but expression in human NCI-H295 adrenocortical carcinoma cells is initiated by two other

31 Accordingly, treatment of adrenocortical carcinoma cells with exogenous HGF result

32 been the mainstay for primary and recurrent adrenocortical carcinoma due to the lack of effective ad

33 previous systemic cytotoxic chemotherapy for adrenocortical carcinoma, Eastern Cooperative Oncology G

34 an important role for HGF/cMET signaling in adrenocortical carcinoma growth and resistance to common

35 ation of the involvement of BMP signaling in adrenocortical carcinoma growth regulation, and the disc

36 The molecular characterization of adrenocortical carcinoma has identified dysregulation of

37 esistance to chemotherapy, but their role in adrenocortical carcinoma has not been examined.

38 No significant advances in the treatment of adrenocortical carcinoma have been developed.

39 ent studies focusing on the tumorigenesis of adrenocortical carcinoma have focused on onco-developmen

40 Adrenocortical carcinoma is a rare cancer that has a poo

41 Adrenocortical carcinoma is a rare malignancy with poor

42 Paediatric adrenocortical carcinoma is a rare malignancy with poor

43 Adrenocortical carcinoma is a rare malignancy, accountin

44 Adrenocortical carcinoma is a rare neoplasm characterize

45 Adrenocortical carcinoma is a rare, aggressive cancer fo

46 Adrenocortical carcinoma is an aggressive, lethal malign

47 d nonfunctional tumors larger than 4 cm when adrenocortical carcinoma is not suspected.

48 ly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in

49 rable progress has occurred in understanding adrenocortical carcinoma pathogenesis from the study of

50 A child with Down syndrome and a history of adrenocortical carcinoma resected at age 1 year presente

51 that increased HGF/cMET expression in human adrenocortical carcinoma samples was positively associat

52 randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either

53 lly confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical site

54 Images of 24 adrenocortical carcinomas were also reviewed to determin

55 In addition, pediatric adrenocortical carcinomas were found to share similar pa

56 nal tumors (16 adenomas, six metastases, one adrenocortical carcinoma) were reviewed.

57 issue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tu

58 noviral vectors suitable for gene therapy of adrenocortical carcinomas with poor prognosis.

59 gamut of clinical presentations, as well as adrenocortical carcinoma, with its advanced disease at p